TP53 and chronic myelogenous leukemia, BCR-ABL1 positive: The SIRT1 is overexpressed in LSCs from CML patients, and inhibition of SIRT1 activates p53 signaling, leading to the enhancement of targeting of CML LSCs by TKI treatment [60].